Plasminogen Activator Inhibitor-1 Polymorphism in Women with Pre-eclampsia

Genetic Testing

Volumn 7, Issue 3, 2003, Pages 265-268

  Häkli, Tanja ^a   Romppanen, Eeva Liisa ^a   Hiltunen, Mikko ^a   Helisalmi, Seppo ^a   Punnonen, Kari ^a   Heinonen, Seppo ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; ARTICLE; CHI SQUARE TEST; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; FEMALE FERTILITY; FINLAND; GENE FREQUENCY; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; HYPERTENSION; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PREECLAMPSIA; PROMOTER REGION; PROTEINURIA; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; CASE-CONTROL STUDIES; FEMALE; FINLAND; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GESTATIONAL AGE; HUMANS; OBSTETRIC LABOR, PREMATURE; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, SINGLE NUCLEOTIDE; PRE-ECLAMPSIA; PREGNANCY; PROMOTER REGIONS (GENETICS);

INSERTION SEQUENCES;

EID: 0242266946     PISSN: 10906576     EISSN: None     Source Type: Journal    
DOI: 10.1089/109065703322537313     Document Type: Article

References (20)

1. ARNGRIMSSON, R., BJÖRNSSON, H., and GEIRSSON, R. (1995). Analysis of different inheritance patterns in preeclampsia/eclampsia syndrome. Hypertension in Pregnancy 14, 27-38.
2. CINCOTTA, R.B., and BRENNECKE, S.P. (1998). Family history of pre-eclampsia as a predictor for pre-eclampsia in primigravidas. Int. J. Gynaecol. Obstet. 60, 23-27.
3. ERIKSSON, P., KALLIN, B., VAN'T HOOFT, F.M., BAVENHOLM, P., and HAMSTEN, A. (1995). Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc. Natl. Acad. Sci. USA 92, 1851-1855.
4. ESTELLES, A., GILABERT, J., KEETON, M., EGUCHI, Y., AZNAR, J., GRANCHA, S., ESPNA, F., LOSKUTOFF, D.J., and SCHLEEF, R.R. (1994). Altered expression of plasminogen activator inhibitor type 1 in placentas from pregnant women with preeclampsia and/or intrauterine fetal growth retardation. Blood 84, 143-150.
5. ESTELLES, A., GILABERT, J., GRANCHA, S., YAMAMOTO, K., THINNES, T., ESPANA, F., AZNAR, J., and LOSKUTOFF, D.J. (1998). Abnormal expression of type 1 plasminogen activator inhibitor and tissue factor in severe preeclampsia. Thromb. Haemost. 79, 500-508.
6. HE, S., BREMME, K., and BLOMBACK, M. (1995). Increased blood flow resistance in placental circulation and levels of plasminogen activator inhibitors types 1 and 2 in severe preeclampsia. Blood Coagul. Fibrinolys. 6, 703-708.
7. LOTTERMOSER, K., DUSING, R., ERVENS, P., KOCH, B., BRUNING, T., SACHINIDIS, A., VETTER, H., and KO, Y. (2001). The plasminogen activator inhibitor 1 4G/5G polymorphism is not associated with longevity: a study in octogenarians. J. Mol. Med. 79, 289-293.
8. MARGAGLIONE, M., GRANDONE, E., CAPPUCCI, G., COLAIZZO, D., GIULIANI, N., VECCHIONE, G., D'ADDEDDA, M., and DI MINNO, G. (1997). An alternative method for PAI-1 promoter polymorphism (4G/5G) typing. Thromb. Haemost. 77, 605-606.
9. MARGAGLIONE, M., CAPPUCCI, G., COLAIZZO, D., GIULIANI, N., VECCHIONE, G., GRANDONE, E., PENNELLI, O., and DI MINNO, G. (1998). The PAI-1 gene locus 4G/ 5G polymorphism is associated with a family history of coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 18, 152-156.
10. MIKKELSSON, J., PEROLA, M., WARTIOVAARA, U., PELTONEN, L., PALOTIE, A., PENTTILA, A., and KARHUNEN, P.J. (2000). Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism, coronary thrombosis, and myocardial infarction in middle-aged Finnish men who died suddenly. Thromb. Haemost. 84, 78-82.
11. PANAHLOO, A., MOHAMED-ALI, V., LANE, A., GREEN, F., HUMPHRIES, S.E., and YUDKIN, J.S. (1995). Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes 44, 37-42.
12. PASTINEN, T., PEROLA, M., NIINI, P., TERWILLIGER, J., SALOMAA, V., VARTIAINEN, E., PELTONEN, L., and SYVANEN, A. (1998). Array-based multiplex analysis of candidate genes reveals two independent and additive genetic risk factors for myocardial infarction in the Finnish population. Hum. Mol. Genet. 7, 1453-1462.
13. PELTONEN, L., JALANKO, A., and VARILO, T. (1999). Molecular genetics of the Finnish disease heritage. Hum. Mol. Genet. 8, 1913-1923.
14. REITH, A., BOOTH, N.A., MOORE, N.R., CRUICKSHANK, D.J., and BENNETT, B. (1993). Plasminogen activator inhibitors (PAI-1 and PAI-2) in normal pregnancies, pre-eclampsia and hydatidiform mole. Br. J. Obstet. Gynaecol. 100, 370-374.
15. SCHWARTZ, C.E., STANISLOVITIS, P., PHELAN, M.C., KLINGER, K., TAYLOR, H.A., and STEVENSON, R.E. (1991). Deletion mapping of plasminogen activator inhibitor, type I (PLANH1) and beta-glucuronidase (GUSB) in 7q21-q22. Cytogenet. Cell Genet. 56, 152-153.
16. SHAARAWY, M., and DIDY, H.E. (1996). Thrombomodulin, plasminogen activator inhibitor type 1 (PAI-1) and fibronectin as biomarkers of endothelial damage in preeclampsia and eclampsia. Int. J. Gynaecol. Obstet. 55, 135-139.
17. VIITANEN, L., PIHLAJAMAKI, J., HALONEN, P., LEHTONEN, M., KAREINEN, A., LEHTO, S., and LAAKSO, M. (2001). Association of angiotensin converting enzyme and plasminogen activator inhibitor-1 promoter gene polymorphisms with features of the insulin resistance syndrome in patients with premature coronary heart disease. Atherosclerosis 157, 57-64.
18. WORKING GROUP ON HIGH BLOOD PRESSURE IN PREGNANCY, (2000). Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am. J. Obstet. Gynecol. 183, S1-S22.
19. YAMADA, N., ARINAMI, T., YAMAKAWA-KOBAYASHI, K., WATANABE, H., SOHDA, S., HAMADA, H., KUBO, T., and HAMAGUCHI, H. (2000). The 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene is associated with severe preeclampsia. J. Hum. Genet. 45, 138-141.
20. YOON, S., TROMP, G., VONGPUNSAWAD, S., RONKAINEN, A., JUVONEN, T., and KUIVANIEMI, H. (1999). Genetic analysis of MMP3, MMP9, and PAI-1 in Finnish patients with abdominal aortic or intracranial aneurysms. Biochem. Biophys. Res. Commun. 265, 563-568.